Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02675595
Other study ID # MD thesis
Secondary ID
Status Recruiting
Phase N/A
First received January 21, 2016
Last updated February 4, 2016
Start date January 2016
Est. completion date May 2018

Study information

Verified date January 2016
Source Ain Shams University
Contact Omneya Nagy Elmakhzangy, Masters
Phone 0020224346370
Email nano_mak@yahoo.co.uk
Is FDA regulated No
Health authority Egypt: Ministry of Health and Population
Study type Observational [Patient Registry]

Clinical Trial Summary

Hypothesis:

In Women in the second trimester of pregnancy 5D offers an alternative method for fetal Echocardiography compared to conventional 2D scanning

Question:

Does 5D software technology is as efficient as 2D scanning in fetal echocardiography of second trimesteric fetuses?

Aim:

This study aims at assessing the accuracy of performance of the 5D as a new scanning technology in fetal Echocardiography compared to the conventional use of 2D scanning.


Description:

Congenital malformations account for more than 20% of all infant deaths(CDC,2014), and congenital heart defects are the most common types of birth defects.

The prenatal diagnosis of major congenital heart defects remains a challenge. Publications by Acherman et al (Acherman RJ .et al) and Sklansky et al (Sklansky MS.et al)have found that approximately 35% of cardiac anomalies are detected prenatally, a frequency that is not substantially different from that documented by Wigton et al in 1993 (Wigton TR, et al) Advances in prenatal ultrasonography have improved prenatal care in recent decades and increased the detection of a large number of congenital malformations. The prenatal detection rate of congenital heart disease (CHD), however, has not shown the same increase as the detection of malformations in other fetal systems (DeVore GR, et al). CHDs are the most commonly overlooked lesions in prenatal screening programs(Garne E et al, Tegnander E et al). This causes concern as CHD represents the most common congenital malformation and is the leading cause of infant mortality in the first year of postnatal life(Garne E). It has been estimated that the prevalence of CHD is 4-8 per 1000 neonates(Hoffman JI et al).

Early detection and accurate prenatal diagnosis of CHD reduces neonatal morbidity and mortality rates by allowing provision of adequate prenatal and postnatal care(Randall P et al, Goncalves LF et al). Before viability is reached, parents can be counseled on the diagnosis, severity and prognosis. Furthermore, it provides parents with the opportunityto make informed decisions on the further course of pregnancy. The four-chamber view has become the standard approach in screening for CHD. Identification of the right and left outflow tracts markedly improves the detection rate of CHD(DeVore GR et al, Stumpflen I et al).

Prenatal detection of these anomalies has proved challenging. In a British study from 1999, Bull(AIUM 2013) reported on 4799 pregnancies affected by major congenital heart defects and found that the antenatal detection rate was only 24%. Lower detection rates were noted in centers that only assessed the 4-chamber view. Correspondingly, in an attempt to improve the antenatal detection rates of congenital heart defects, the American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, and International Society of Ultrasound in Obstetrics and Gynecology all have recommended that an attempt should be made to image the ventricular outflow tracts during the fetal anatomic survey.( Carvalho JS et al. , Bull C., AIUM 2003)

However, imaging of these outflow tracts can be challenging, and it is not clear that they can be typically obtained in generalized non-tertiary care settings. A 2007 study from the United States, which included 77,000 births, found that only 36% of major congenital heart defects were detected antenatally. It is not clear from the study whether outflow views were routinely obtained at all of the laboratories involved, but the study suggests that better detection rates could be achieved if outflow views were more routinely imaged.( Bull C. )

In an effort to improve antenatal detection of these anomalies, the American Institute of Ultrasound in Medicine, the American College of Obstetricians and Gynecologists, and the International Society of Ultrasound in Obstetrics and Gynecology have suggested that routine ultrasound examinations should attempt to include views of the cardiac outflow tracts. (AIUM 2003)

The myriad of fetal positions and the different maternal factors that influence the examination make fetal echocardiography one of the more difficult tasks for sonographers. To help improve and standardize fetal cardiac examinations, Yagel et al. and Yoo et al. described a method in which five cardiac planes are visualizedfor a complete examination of the fetal heart(Yoo SJ et al,Yagel et al ). Additionally, three- and four-dimensional (3D and 4D) ultrasound imaging can be a valuable tool in fetal echocardiography(ACOG 2004, Chaoui R et al,AIUM 2010, Yagel S et al M. C. Haak et al , Luciane Alves Rocha et al Rocha LA et al )

Other proposals have included obtaining routine 2-dimensional (2D) cine clips, universal fetal echocardiography, and routine use of 3-dimensional (3D) fast acquisition volumes. One reason that 3D sonographic technologies have been suggested is because routine visualization of cardiac views has proven to be a challenge with 2D imaging in centers that are less experienced with prenatal diagnosis, and 3D stored volumes could then be evaluated further by those more experienced.( M. C. Haak et al , Luciane Alves Rocha, et al, Rocha LA et al )

Fetal Intelligent Navigation Echocardiography (FINE) 5D work flow refers to semi-automated identification of specific diagnostic image planes and measurements from a volume dataset simultaneously displaying nine standard fetal cardiac views. It allows the examination of cardiac planes, such as the axial planes and view of the interventricular septum (IVS plane) which are technically very difficult to image using conventional two-dimensional (2D) echocardiography (Rocha LA et al).

However, to be an effective tool in fetal echocardiography, 5D volume acquisition must be feasible in routine clinical practice. A number of reports on these new technologies have emphasized the requirement of a substantial learning curve for the use of 5D ultrasound imaging(M. C. Haak et al , Luciane Alves Rocha et al ). This may explain the delay in widespread introduction of this new technique in first- and second level ultrasound departments, and even in tertiary referral centers.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date May 2018
Est. primary completion date January 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Living fetus.

- Singleton

- No gross fetal structural malformation

- No maternal Medical Disorders

- G.A : in between 20-26 wks.

- Verbal consent informing the aim and process of this study

Exclusion Criteria:

- the fetal spine between the 9- and 3-o'clock positions

- Missed Abortion.

- women with body mass index (BMI) =30 kg/m2

- GA : before 20 wk.

- presence of polyhydramnios or oligohydramnios (amniotic fluid index >95th percentile or < 5th percentile)

- Detectable or suspected fetal cardiac anomaly

- Fetal congenital malformation

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Ain Shams University Hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Obtaining standard 9 views of fetal echocardiography by 5D as well as 2D All 80 fetuses will undergo 2D and 5D detailed fetal echocardiography to obtain the standard nine cardiac views according to standards set by AIUM (American Institute of Ultrasound in Medicine) and both modalities will be compared by their ability to obtain the nine standard cardiac views. 2 years No
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02528136 - The Clinical Carbetocin Myocardium Trial Phase 4